Are Genelux (USA Stocks:GNLX) investors shifting to Intel (USA Stocks:INTC)?

GNLX Stock

30.47 0.47 1.57%

Macroaxis Story

As many rational traders are trying to avoid healthcare space, it makes sense to break down Genelux Common a little further and understand how it stands against Intel and other similar entities. We are going to inspect some of the competitive aspects of both Genelux and Intel.

Published over a month ago

View all stories for Genelux Common | View All Stories

Macroaxis uses a strict editorial review process to publish our stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.

Reviewed by Vlad Skutelnik

By analyzing existing essential indicators between Genelux Common and Intel, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Intel with a short position in Genelux Common. Check out our pair correlation module for more information.

Let's begin by analyzing the assets.

The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of Genelux suggests not a very effective usage of assets in February.

Are Genelux (USA Stocks:GNLX) investors shifting to Intel (USA Stocks:INTC)?

How does Genelux utilize its cash?

To perform a cash flow analysis of Genelux Common, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Genelux Common is receiving and how much cash it distributes out in a given period. The Genelux Common cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Genelux Common Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Genelux Common reported Net Cash Flow from Operations of (7.57 Million) in 2022

Purchase by Zhang Qian of 200 shares of Genelux Common

Legal trades by Genelux Common insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Genelux insider trading alert for perchase of common stock by Zhang Qian, Associate VP Research, on 31st of January 2023. This event was filed by Genelux Corp with SEC on 2023-01-31. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Genelux Common

Total Debt Breakdown

Let me now analyze Genelux Common total debt. Based on the latest financial disclosure, Genelux Common has a Total Debt of 18.02 M. This is 99.34% lower than that of the Healthcare sector and 94.45% lower than that of the Biotechnology industry. The total debt for all United States stocks is 99.66% higher than that of Genelux Common. As for Intel we see total debt of 37.68 B, which is much higher than that of the Biotechnology

INTC

37.7 B

GNLX	18.02 Million	0.0474
Sector	324.78 Million	0.85
INTC	37.68 Billion	99.1

Another 3 percent rise for Genelux Common

Current value at risk indicator falls down to -3.88. Possible price jump?

As of the 24th of February, Genelux Common retains the Risk Adjusted Performance of 0.3887, downside deviation of 3.06, and Market Risk Adjusted Performance of 33.15. Genelux Common technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Genelux Common, which can be compared to its competitors. Please check out Genelux Common coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Genelux Common is priced fairly, providing market reflects its last-minute price of 10.86 per share. Given that Genelux Common has jensen alpha of 2.51, we strongly advise you to confirm Genelux Common's regular market performance to make sure the company can sustain itself at a future point.

Our Conclusion on Genelux Common

While many other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Genelux Common may offer a potential longer-term growth to investors. To conclude, as of the 24th of February 2023, our analysis shows that Genelux Common barely shadows the market. The company is overvalued and projects low probability of distress for the next 2 years. However, our ongoing 90 days recommendation on the company is Strong Buy.

Editorial Staff

Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Genelux Common. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2023 Macroaxis LLC